Search results
Some hawking stem cells say they can treat almost anything. They can’t
WWTI Watertown· 1 day agoThe mailings promised “Life Without Pain!” via stem cell injections or IVs administered in a...
...BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE...
Morningstar· 2 days agoAmgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved BLINCYTO® (blinatumomab) for the treatment of adult and pediatric patients one ...
Intestinal organoids reveal the mechanism of gastrointestinal motility
Medical Xpress· 2 days agoUsing single-cell optical tweezers, the researchers measured EEC stiffness profiles at the physiological temperature and investigated changes following tryptophan metabolism ...
People Are Recalling Things That Happened In 2001 That Were Overshadowed By 9/11
BuzzFeed via Yahoo News· 8 hours agoIt happened three weeks before 9/11." Phil Carpenter / AFP via Getty Images 3."George W. Bush issued...
Growing Out Your Hair? Try Taking More of These Vitamins for Long, Lush Locks
CNET· 4 days agoHave trouble growing long, healthy hair? Many people struggle with hair thinning and damage that may...
Analysts Set Expectations for BioRestorative Therapies, Inc.’s FY2027 Earnings (NASDAQ:BRTX)
ETF DAILY NEWS· 2 days agoBioRestorative Therapies, Inc. (NASDAQ:BRTX – Free Report) – Roth Capital decreased their FY2027 earnings estimates for shares of BioRestorative Therapies in a report issued on Wednesday, June ...
...STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or...
Morningstar· 1 day agoGenentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma – The study met ...
Pilot study explores new approach for reducing anxiety and improving quality of life after stem cell...
Medical Xpress· 5 days agoThe findings indicate that the PATH intervention is both feasible and well-received by this patient...
Rigel Announces Five Presentations at the EHA2024 Hybrid Congress
Tehachapi News· 2 days ago- Oral presentation highlighting final five-year efficacy data from the registrational Phase 2 trial of REZLIDHIA® (olutasidenib) in heavily pretreated patients with R/R mIDH1 AML, including those receiving prior venetoclax
A Guide to Managing COVID This Summer
New York Times· 4 days agoHere’s what to know about symptoms, testing and treatment. As new variants of the coronavirus continue to gain traction, doctors and researchers are...